title: Thiazolidinediones and antiblastics in primary human anaplastic thyroid cancer cells.
abstract: OBJECTIVE
  No study has evaluated the antiproliferative effects of thiazolidinediones and antiblastics in 'primary cultured human anaplastic thyroid cancer cells'.
  
  
  METHODS
  Primary anaplastic cells proliferation was evaluated after incubation with increasing concentrations of rosiglitazone or pioglitazone or antiblastics (bleomycin, cisplatin, gemcitabine) by a proliferation assay (WST-1-tetrazolium reaction) and cell counting.
  
  
  RESULTS
  A reduction of proliferation by thiazolidinediones at 1 h (from the start of tetrazolium reaction) [of 11% and 25%, with rosiglitazone, 10 or 20 (P = 0.0001) microM, respectively; of 7% and 17%, with pioglitazone, 10 or 20 (P = 0.0125) microM, respectively], and at 2 h [of 14% and 24%, with rosiglitazone, 10 (P = 0.0043) or 20 (P < 0.0001) microM, respectively; of 9% and 21%, with pioglitazone, 10 (P = 0.0397) or 20 (P = 0.0001) microM, respectively] was shown. No significant thiazolidinediones effect was observed in normal thyroid follicular cells. Bleomycin, cisplatin and gemcitabine significantly (P < 0.0001) inhibited (> 50%) anaplastic cells proliferation. Cell counting confirmed the above mentioned results. Inhibition of proliferation was similar in tumours with or without (V600E)BRAF mutation, both for thiazolidinediones and antiblastics.
  
  
  CONCLUSIONS
  Thiazolidinediones exert an antiproliferative effect in primary cultured human anaplastic carcinoma cells in vitro, such as antiblastics.
authors.affiliation: Department of Internal Medicine, University of Pisa, via Roma, 67, I-56100, Pisa, Italy. a.antonelli@med.unipi.it
authors.forename: Alessandro
authors.initials: A
authors.lastname: Antonelli
authors.forename: Silvia Martina
authors.initials: SM
authors.lastname: Ferrari
authors.forename: Poupak
authors.initials: P
authors.lastname: Fallahi
authors.forename: Piero
authors.initials: P
authors.lastname: Berti
authors.forename: Gabriele
authors.initials: G
authors.lastname: Materazzi
authors.forename: Michele
authors.initials: M
authors.lastname: Minuto
authors.forename: Riccardo
authors.initials: R
authors.lastname: Giannini
authors.forename: Ivo
authors.initials: I
authors.lastname: Marchetti
authors.forename: Lucio
authors.initials: L
authors.lastname: Barani
authors.forename: Fulvio
authors.initials: F
authors.lastname: Basolo
authors.forename: Ele
authors.initials: E
authors.lastname: Ferrannini
authors.forename: Paolo
authors.initials: P
authors.lastname: Miccoli
mesh_terms: D002277:Carcinoma / Q000188:drug therapy* / Q000503:physiopathology; D049109:Cell Proliferation / Q000187:drug effects*; D006131:Growth Inhibitors / Q000494:pharmacology*; D006801:Humans; D000077205:Pioglitazone; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000494:pharmacology* / Q000627:therapeutic use; D013964:Thyroid Neoplasms / Q000188:drug therapy* / Q000503:physiopathology; D014407:Tumor Cells, Cultured
chemical_list: D006131:Growth Inhibitors; D045162:Thiazolidinediones; D000077154:Rosiglitazone; D000077205:Pioglitazone